High Versus Standard Volume Hemodiafiltration in Asia
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- Patients on thrice-weekly standard hemodialysis for > 3 months
- Patients willing to provide written informed consent.
- Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
- Patients on thrice-weekly standard hemodialysis for > 3 months
- Patients willing to provide written informed consent.
- Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Exclusion Criteria
- Patients considered by investigator to have difficulty in participation
- Patients whose life expectancy < 12 months
- Patients with active infectious or uncontrolled inflammatory disorders
- ...
- Patients considered by investigator to have difficulty in participation
- Patients whose life expectancy < 12 months
- Patients with active infectious or uncontrolled inflammatory disorders
- Patients with recent major cardiovascular disease during the last 6 months
- Patients with any uncontrolled malignant disease
- Patients who are likely to receive kidney transplant within the following 1 year
Summary
- Conditions
- End Stage Renal Disease
- End-stage Renal Disease
- Type
- Interventional
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 75 years
- Gender
- Both males and females
Inclusion Criteria
- Patients on thrice-weekly standard hemodialysis for > 3 months
- Patients willing to provide written informed consent.
- Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
- Patients on thrice-weekly standard hemodialysis for > 3 months
- Patients willing to provide written informed consent.
- Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Exclusion Criteria
- Patients considered by investigator to have difficulty in participation
- Patients whose life expectancy < 12 months
- Patients with active infectious or uncontrolled inflammatory disorders
- ...
- Patients considered by investigator to have difficulty in participation
- Patients whose life expectancy < 12 months
- Patients with active infectious or uncontrolled inflammatory disorders
- Patients with recent major cardiovascular disease during the last 6 months
- Patients with any uncontrolled malignant disease
- Patients who are likely to receive kidney transplant within the following 1 year
Tracking Information
- NCT #
- NCT02092194
- Collaborators
- Boryung Pharmaceutical Co., Ltd
- Investigators
- Study Director: Won-Yong Cho, MD Korea University
Get Well Soon